Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Spyre Therapeutics Inc shares valued at $460,134 were sold by Turtle Cameron on Jan 02 ’26. At $30.68 per share, Turtle Cameron sold 15,000 shares. The insider’s holdings dropped to 671,907 shares worth approximately $20.25 million following the completion of this transaction.
Also, Turtle Cameron sold 15,000 shares, netting a total of over 435,356 in proceeds. Following the sale of shares at $29.02 each, the insider now holds 686,907 shares.
Before that, Turtle Cameron had sold 45,000 shares from its account. In a trade valued at $1,049,778, the Chief Executive Officer traded Spyre Therapeutics Inc shares for $23.33 each. Upon closing the transaction, the insider’s holdings decreased to 45,000 shares, worth approximately $21.16 million.
As published in their initiating research note from Mizuho on December 18, 2025, Spyre Therapeutics Inc [SYRE] has been an Outperform and the price target has been revised to $53. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. As of September 26, 2025, Deutsche Bank has initiated its “Buy” rating for SYRE. Earlier on April 08, 2025, Leerink Partners initiated its rating. Their recommendation was “an Outperform” for SYRE stock.
Analyzing SYRE Stock Performance
On last trading session, Spyre Therapeutics Inc [NASDAQ: SYRE] plunged -2.93% to $30.14. The stock’s lowest price that day was $29.6, but it reached a high of $30.7 in the same session. During the last five days, there has been a drop of approximately -8.00%. Over the course of the year, Spyre Therapeutics Inc shares have jumped approximately 23.42%. Shares of the company reached a 52-week high of $33.31 on 01/02/26 and a 52-week low of $28.00 on 01/05/26.
Support And Resistance Levels for Spyre Therapeutics Inc (SYRE)
According to the 24-hour chart, there is a support level at 29.59, which, if violated, would cause prices to drop to 29.04. In the upper region, resistance lies at 30.70. The next price resistance is at 31.25. RSI (Relative Strength Index) is 45.34 on the 14-day chart, showing neutral technical sentiment.
Is Spyre Therapeutics Inc subject to short interest?
Stocks of Spyre Therapeutics Inc saw a sharp steep in short interest on 2025-12-15 dropping by -0.65 million shares to 11.82 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 12.46 million shares. A decline of -5.47% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 15.65 of the overall float, the days-to-cover ratio (short ratio) decline to 15.65.
Which companies own the most shares of Spyre Therapeutics Inc (SYRE)?
In terms of Spyre Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 48 in the next 12 months, up nearly 54.59% from the previous closing price of $31.05. Analysts anticipate Spyre Therapeutics Inc stock to reach 53 by 2026, with the lowest price target being 43. In spite of this, 3 analysts ranked Spyre Therapeutics Inc stock as Buy at the end of 2026. On March 18, 2025, Wolfe Research assigned a price target of “an Outperform” to the stock and initiated coverage with a $27.
